BFHIV Financials
Newest figures come from the 10-Q for Q1 FY2026, filed Apr 28, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BFHIV SEC filings page.
BFHIV (BFHIV) reported $3.9B in revenue over the twelve months to Mar 31, 2026, up 2.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is roughly flat, but FY2025 earnings recovered while debt fell, leaving a less liability-heavy balance sheet.
Revenue rose just0.5% from FY2022 to FY2025, while net income rose132.3% ; this is a profit-recovery pattern rather than volume-led growth. Operating cash flow rose13.2% over that span, and FY2025 cash flow was403.9% of net income, so reported profit translated into more cash but less dramatically than earnings improved.
Debt declined
SG&A fell
Financial Health Signals
We do not publish a peer-relative financial health score for BFHIV, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
BFHIV passes 7 of 7 computable financial strength tests (2 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) passes.
For every $1 of reported earnings, BFHIV generates $4.04 in operating cash flow ($2.1B OCF vs $518.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
BFHIV generated $1.0B in revenue in Q1 2026. This represents an increase of 4.9% from the same quarter a year earlier. Against the prior quarter it is up 4.4%.
BFHIV reported $181.0M in net income in Q1 2026. This represents an increase of 31.2% from the same quarter a year earlier. Against the prior quarter it is up 241.5%.
BFHIV earned $4.15 per diluted share (EPS) in Q1 2026. This represents an increase of 49.3% from the same quarter a year earlier.
Not reported for Q1 2026.
Cash & Balance Sheet
BFHIV held $3.6B in cash as of Q1 2026; no long-term debt figure is on record for that period.
BFHIV paid $0.23 per share in dividends in Q1 2026. This represents an increase of 9.5% from the same quarter a year earlier. It is unchanged from the prior quarter.
Not reported for Q1 2026.
Margins & Returns
BFHIV's net profit margin was 17.8% in Q1 2026, showing the share of revenue converted to profit. This is up 3.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 12.3 percentage points.
BFHIV's quarterly ROE was 5.4% in Q1 2026: one quarter's net income over shareholder equity, not annualized. This is up 0.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.8 percentage points.
Not reported for Q1 2026.
Not reported for Q1 2026.
Capital Allocation
BFHIV spent $153.0M on share buybacks in Q1 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 48.5% from the same quarter a year earlier. Against the prior quarter it is up 24.4%.
Not reported for Q1 2026.
Not reported for Q1 2026.
BFHIV Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'25 | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0B+4.9% | $975.0M+5.4% | $971.0M-1.2% | $929.0M-1.1% | $970.0M-2.1% | $925.0M-9.0% | $983.0M-4.7% | $939.0M-1.4% |
| SG&A Expenses | $472.0M-1.0% | $554.0M+3.6% | $476.0M-17.1% | $481.0M+2.6% | $477.0M-1.0% | $535.0M+3.7% | $574.0M+14.3% | $469.0M-11.5% |
| Interest Expense | $193.0M-14.2% | $199.0M-13.9% | $210.0M-12.5% | $220.0M-8.7% | $225.0M-9.3% | $231.0M-2.5% | $240.0M+9.6% | $241.0M+17.6% |
| Income Tax | $62.0M+12.7% | -$4.0Mn/m | $8.0M-78.4% | $35.0M-25.5% | $55.0M+3.8% | -$35.0Mn/m | $37.0M-28.8% | $47.0M+113.6% |
| Net Income | $181.0M+31.2% | $53.0M+562.5% | $188.0M+9300.0% | $139.0M+4.5% | $138.0M+3.0% | $8.0M-81.8% | $2.0M-98.8% | $133.0M+177.1% |
| EPS (Basic) | $4.19+49.1% | N/A | $4.04+7980.0% | $2.97+10.4% | $2.81+3.7% | N/A | $0.05-98.5% | $2.69+183.2% |
| EPS (Diluted) | $4.15+49.3% | N/A | $3.96+7820.0% | $2.94+10.5% | $2.78+3.0% | N/A | $0.05-98.5% | $2.66+180.0% |
| Diluted Shares (Avg) | 43M-12.9% | N/A | 48M-6.9% | 47M-6.0% | 50M-0.2% | N/A | 51M+1.8% | 50M-0.2% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, Operating Income, EBITDA.
BFHIV Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'25 | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $22.3B-0.3% | $22.7B-1.0% | $21.7B-0.1% | $21.8B-1.5% | $22.4B+0.4% | $22.9B-1.1% | $21.7B+0.6% | $22.1B+2.5% |
| Cash & Equivalents | $3.6B-13.7% | $3.6B-2.0% | $3.8B+9.1% | $3.8B-6.3% | $4.2B+11.2% | $3.7B+2.5% | $3.5B+2.1% | $4.1B+21.9% |
| Accounts Receivable | N/A | $148.0M+2.1% | N/A | N/A | N/A | $145.0M+0.7% | N/A | N/A |
| Goodwill | N/A | $634.0M0.0% | N/A | N/A | N/A | $634.0M0.0% | N/A | N/A |
| Total Liabilities | $19.0B-1.7% | $19.3B-2.5% | $18.4B-1.2% | $18.7B-1.7% | $19.3B+0.2% | $19.8B-1.9% | $18.6B-0.6% | $19.0B+0.5% |
| Long-Term Debt | N/A | $4.3B-22.5% | $3.8B-17.4% | $4.2B | $5.1B | $5.6B+5.0% | $4.6B+8.5% | N/A |
| Total Equity | $3.3B+8.4% | $3.3B+9.0% | $3.3B+6.6% | $3.2B-0.1% | $3.1B+1.2% | $3.1B+4.6% | $3.1B+8.7% | $3.2B+15.9% |
| Retained Earnings | $1.6B+45.9% | $1.5B+47.6% | $1.4B+42.8% | $1.3B+24.0% | $1.1B+26.5% | $999.0M+30.2% | $1.0B+36.5% | $1.0B+76.3% |
Not reported in any period shown, so not listed: Current Assets, Short-Term Investments, Inventory, Long-Term Investments, Current Liabilities, Non-Current Liabilities.
BFHIV Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'25 | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $487.0M+23.9% | $568.0M+18.6% | $605.0M+32.7% | $526.0M+10.3% | $393.0M-12.1% | $479.0M-22.4% | $456.0M-27.5% | $477.0M+39.1% |
| Depreciation & Amortization | $19.0M-9.5% | $19.0M-13.6% | $20.0M-9.1% | $20.0M-13.0% | $21.0M-8.7% | $22.0M-8.3% | $22.0M-4.3% | $23.0M-34.3% |
| Stock-Based Compensation | $15.0M+15.4% | N/A | $14.0M+7.7% | $15.0M+7.1% | $13.0M-13.3% | N/A | $13.0M+30.0% | $14.0M+16.7% |
| Investing Cash Flow | $317.0M-54.1% | -$1.5Bn/m | -$338.0Mn/m | -$221.0M-812.9% | $691.0M-4.0% | -$1.4Bn/m | -$569.0Mn/m | $31.0Mn/m |
| Financing Cash Flow | -$475.0Mn/m | $784.0M-29.7% | -$306.0Mn/m | -$723.0Mn/m | -$562.0Mn/m | $1.1B-20.1% | -$488.0Mn/m | -$244.0Mn/m |
| Dividends Paid | $10.0M0.0% | $10.0M-9.1% | $10.0M0.0% | $10.0M-9.1% | $10.0M-9.1% | $11.0M+10.0% | $10.0M-9.1% | $11.0M0.0% |
| Share Buybacks | $153.0M+48.5% | $123.0M+179.5% | $40.0Mn/m | $47.0Mn/m | $103.0M+836.4% | $44.0Mn/m | $0-100.0% | $0n/m |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow.
BFHIV Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'25 | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Net Margin | 17.8%+3.6pp | 5.4%+4.6pp | 19.4%+19.2pp | 15.0%+0.8pp | 14.2%+0.7pp | 0.9%-3.5pp | 0.2%-16.4pp | 14.2%+9.1pp |
| Return on Equity | 5.4%+0.9pp | 1.6%+1.3pp | 5.7%+5.6pp | 4.4%+0.2pp | 4.5%+0.1pp | 0.3%-1.3pp | 0.1%-5.9pp | 4.2%+2.5pp |
| Return on Assets | 0.8%+0.2pp | 0.2%+0.2pp | 0.9%+0.9pp | 0.6%0.0pp | 0.6%0.0pp | 0.0%-0.2pp | 0.0%-0.8pp | 0.6%+0.4pp |
| Debt-to-Equity | N/A | 1.29-0.5x | 1.14-0.3x | 1.34 | 1.67 | 1.820.0x | 1.470.0x | N/A |
| Liabilities-to-Equity | 5.71-0.6x | 5.81-0.7x | 5.55-0.4x | 5.89-0.1x | 6.30-0.1x | 6.50-0.4x | 5.98-0.6x | 5.99-0.9x |
| Asset Turnover | 0.050.0x | 0.040.0x | 0.040.0x | 0.040.0x | 0.040.0x | 0.040.0x | 0.050.0x | 0.040.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Current Ratio, FCF Margin.
Where BFHIV Ranks
Frequently Asked Questions
BFHIV (BFHIV) reported $3.8B in total revenue for fiscal year 2025. This represents a 0.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
BFHIV (BFHIV) revenue grew by 0.2% year-over-year, from $3.8B to $3.8B in fiscal year 2025.
Yes, BFHIV (BFHIV) reported a net income of $561.0M over the trailing 12 months to March 31, 2026. In fiscal year 2025 it reported a net income of $518.0M, with a net profit margin of 13.5%.
As of fiscal year 2025, BFHIV (BFHIV) had $3.6B in cash and equivalents against $4.3B in long-term debt.
BFHIV (BFHIV) had a net profit margin of 13.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Yes, BFHIV (BFHIV) paid $0.86 per share in dividends during fiscal year 2025.
BFHIV (BFHIV) has a return on equity of 15.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
BFHIV (BFHIV) generated $2.1B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
BFHIV (BFHIV) had $22.7B in total assets as of fiscal year 2025, including both current and long-term assets.
BFHIV (BFHIV) had a debt-to-equity ratio of 1.29 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
BFHIV (BFHIV) had a liabilities-to-equity ratio of 5.81 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
BFHIV (BFHIV) had a return on assets of 2.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
BFHIV (BFHIV) has a Piotroski F-Score of 7 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
BFHIV (BFHIV) has an earnings quality ratio of 4.04x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.